GSK Partners with Vodafone for Vaccinations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Partners with Vodafone for Vaccinations


ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline has formed a partnership with Vodafone to use mobile technology to help vaccinate more children against common infectious diseases in Africa.

Initially, the project will focus on Mozambique for a one-year pilot project examining whether mobile technology solutions can help encourage mothers to take up vaccination services, support health workers, and enable better management of vaccine stock. According to a press statement, the pilot will seek to boost vaccination in the country by 5–10%.

“Innovative technologies – whether mobile devices, medicines or vaccines – are helping to transform global health. Organizations such as UNICEF and GAVI have played a key role in making vaccines much more accessible in Africa but barriers still exist which stop children from benefiting from basic immunization,” Sir Andrew Witty, CEO of GSK, said in a statement.

Mothers and caregivers will be registered on a database and alerted by SMS about the availability of vaccinations. Appointments can also be scheduled by SMS and notifications will help to ensure that children complete the full schedule of vaccinations. Health workers will be given smartphones with software that allows them to contact mothers, view and record vaccination histories, schedule vaccinations and report on follow-up visits.

For supply-chain management, healthcare facilities will be prompted to report on vaccine stock levels by SMS.

The project will be supported by the Save the Children organization and the Mozambique Ministry of Health. Up to 100 clinics will be included and the project will be independently tested to prove its impact, effectiveness and cost benefits.

Witty added, “This new partnership combines GSK’s expertise, knowledge and resources with those of Vodafone with the potential to deliver life-saving vaccines to tens of thousands more children in Mozambique. Our hope is that together we will create a sustainable and scalable model which could ultimately be replicated to help more children live healthy lives across developing countries.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here